Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit

Alterity Therapeutics ( (AU:ATH) ) has shared an announcement.

Alterity Therapeutics, a clinical-stage biotech focused on disease-modifying treatments for Multiple System Atrophy and related Parkinsonian disorders, is advancing its lead asset ATH434 following positive Phase 2 data and leveraging a discovery platform aimed at novel neurological therapies. The company operates from Melbourne and San Francisco, positioning itself within the rare neurodegenerative disease segment with a late-stage pipeline candidate.

The company announced that CEO David Stamler will participate in the Bell Potter Healthcare Horizons Summit in Sorrento, Australia, where he will join a fireside chat on optimizing late-stage clinical trials and hold one-on-one investor meetings. The appearance underscores Alterity’s efforts to highlight its upcoming Phase 3 pivotal trial in MSA and engage the investment community as it seeks to strengthen its profile and support for its late-stage development plans.

The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative conditions, with a primary focus on Multiple System Atrophy and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in a randomized, placebo-controlled Phase 2 trial and positive results in an open-label Phase 2 study in advanced MSA, supported by a broader platform generating patentable compounds targeting neurological disease pathology.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$76.13M

See more insights into ATH stock on TipRanks’ Stock Analysis page.